Vida Health, Oura Partner on Continuous Metabolic Care as Smart Ring Maker Expands Clinical & AI Ambition

As Oura pushes beyond consumer wearables into gesture tech, clinical integrations and enterprise partnerships, its latest collaboration with Vida Health signals a broader shift toward continuous, data-driven care

Vida Health is partnering with Oura to bring continuous biometric monitoring into clinician-led metabolic care, expanding the wearable brand’s larger ambitions toward continuous care.

The collaboration integrates real-time data from the Oura Ring into Vida’s virtual cardiometabolic programs, giving care teams access to ongoing signals like sleep, heart rate variability and resting heart rate alongside clinical and behavioral data. The goal is to move beyond episodic care models and enable earlier interventions.

“Providers are often making decisions based on limited snapshots,” said Richard Frank, MD, Chief Medical Officer at Vida Health. “What’s been missing is a continuous view of how patients are actually doing day to day.”

By embedding wearable data directly into care, Vida can refine treatment plans dynamically. The approach is designed to improve engagement and adherence, persistent challenges in managing chronic conditions like obesity, diabetes and hypertension.

Oura, now valued at roughly $11 billion, has been gradually layering in clinical and enterprise capabilities, including partnerships that put its biometric data directly into the hands of providers and health systems.

In March, Oura acquired Doublepoint, a gesture-recognition startup focused on enabling wearables to detect subtle hand movements. The deal signals a push toward more intuitive, ambient computing experiences, where devices like the Oura Ring could function as control interfaces for digital and physical environments. The brand is also deepening its enterprise presence, including longstanding work with the U.S. Department of Defense, where its devices are used for fatigue management, stress resilience and early illness detection.

Oura has also introduced a proprietary AI model focused on women’s health and expanded integrations with clinical platforms, enabling providers to incorporate continuous biometric data into treatment decisions.

“One of the biggest gaps in healthcare is making continuous data clinically useful. Metabolic care extends beyond a single lab value or prescription and depends on how sleep, activity, stress and daily routines interact over time,” said Ricky Bloomfield, MD, Chief Medical Officer at Oura. “This joint effort gives care teams timely, contextual information to guide treatment decisions, outreach, and behavior-change support grounded in longitudinal trends rather than isolated readings, helping them better understand how members are doing between visits and respond more effectively.”